Trial · NCT01800201

Automated Hovering to Improve Medication Adherence Among Myocardial Infarction Patients (Heartstrong)

NCT01800201, Not applicable, Completed, University of Pennsylvania; results first posted 2020-01-18

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Automated Hovering to Improve Medication Adherence Among Myocardial Infarction Patients (Heartstrong). Trials, record NCT01800201. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01800201

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Automated Hovering to Improve Medication Adherence Among Myocardial Infarction Patients (Heartstrong)
NCT number: NCT01800201
Status: Completed
Phases: Not applicable
Enrollment: 1,509 participants, actual
Lead sponsor: University of Pennsylvania
Conditions: Patients With Principal or Secondary Diagnosis Code of Intrntl Classification of Diseases, 9th Revision, (ICD-9-CM) 410 (Except When 5th Digit Was 2)
Interventions: Electronic Pill Bottle, Incentives, Social Influence
First posted: 2013-02-27
Last updated: 2020-01-18
Results first posted: 2020-01-18

Source ClinicalTrials.gov

Registered outcomes4

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	1 -Year Survival Probability Rate: Vascular Readmissions or Death	Date of enrollment + 12 months	Primary outcome variable(s): 1- year survival probability rate for vascular inpatient readmission or death
Secondary	1 Year Survival Probability Rate All Cause Readmissions	Date of enrollment + 12 months	1 year survival probability rate for all cause readmissions
Secondary	Total Vascular Inpatient Readmissions	Date of enrollment + 12 months	This is the number of vascular inpatient admission events control vs. intervention
Secondary	Proportion of Days Covered (PDC) for a Subset of Patients for Whom we Have Prescription Information	12 months	Calculated by the proportion of days in which a patient has an active medication for all three medications (statin, beta blocker and antiplatelet). It is not the weighted average of the individual medication. This reflects the "intermediate" definition of adherence: our intermediate definition assumed that patients had been prescribed a medication for the entire study period if they ever filled that medication after discharge

Source ClinicalTrials.gov

Outcomes4

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Units	Measured as
PRIMARY	1 -Year Survival Probability Rate: Vascular Readmissions or Death	Date of enrollment + 12 months	proportion of participants	NUMBER
SECONDARY	1 Year Survival Probability Rate All Cause Readmissions	Date of enrollment + 12 months	proportion of participants	NUMBER
SECONDARY	Total Vascular Inpatient Readmissions	Date of enrollment + 12 months	readmissions	NUMBER
SECONDARY	Proportion of Days Covered (PDC) for a Subset of Patients for Whom we Have Prescription Information	12 months	PDC, mean	MEAN

Source ClinicalTrials.gov

Results by group8

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Spread	Units
1 -Year Survival Probability Rate: Vascular Readmissions or Death	Control	.91		proportion of participants
1 -Year Survival Probability Rate: Vascular Readmissions or Death	Intervention	.91		proportion of participants
1 Year Survival Probability Rate All Cause Readmissions	Control	.65		proportion of participants
1 Year Survival Probability Rate All Cause Readmissions	Intervention	.69		proportion of participants
Total Vascular Inpatient Readmissions	Control	62		readmissions
Total Vascular Inpatient Readmissions	Intervention	119		readmissions
Proportion of Days Covered (PDC) for a Subset of Patients for Whom we Have Prescription Information	Control	.58	Standard Deviation 0.35	PDC, mean
Proportion of Days Covered (PDC) for a Subset of Patients for Whom we Have Prescription Information	Intervention	.61	Standard Deviation 0.33	PDC, mean

Source ClinicalTrials.gov

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Control	506
Overall Study	STARTED	Intervention	1,003
Overall Study	COMPLETED	Control	503
Overall Study	COMPLETED	Intervention	1,000
Overall Study	NOT COMPLETED	Control	3
Overall Study	NOT COMPLETED	Intervention	3

Source ClinicalTrials.gov

Adverse events16

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
serious	Intracranial Hemmorhage	Cardiac disorders	Control	0	503	0
serious	Intracranial Hemmorhage	Cardiac disorders	Intervention	5	1,000	7
serious	Liver Failure	Renal and urinary disorders	Control	1	503	1
serious	Liver Failure	Renal and urinary disorders	Intervention	1	1,000	1
serious	Heart Block	Cardiac disorders	Control	1	503	1
serious	Heart Block	Cardiac disorders	Intervention	4	1,000	6
serious	Rhabdomyolysis	Renal and urinary disorders	Control	1	503	1
serious	Rhabdomyolysis	Renal and urinary disorders	Intervention	4	1,000	4
serious	GI Hemmorhage/Ulcer	Gastrointestinal disorders	Control	12	503	16
serious	GI Hemmorhage/Ulcer	Gastrointestinal disorders	Intervention	12	1,000	14

1 to 10 of 16Source ClinicalTrials.gov

See all 16 adverse events

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Control	4	503
Total, all-cause mortality	Intervention	8	1,000
Total, other adverse events	Control	0	503
Total, other adverse events	Intervention	0	1,000
Total, serious adverse events	Control	37	503
Total, serious adverse events	Intervention	66	1,000

Source ClinicalTrials.gov

Papers1

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as
28654972	BACKGROUND

Source PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons2

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison	Source
Intervention vs Control: deaths from any cause	Trial comparisons
Intervention vs Control: serious adverse events	Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT01800201

GET https://conductscience.org/api/trials/v1/NCT01800201/registered

API reference For AI assistants